Equity Overview
Price & Market Data
Price: $12.89
Daily Change: +$0.24 / 1.86%
Range: $12.11 - $12.94
Market Cap: $349,574,240
Volume: 335,871
Performance Metrics
1 Week: 25.15%
1 Month: 0.94%
3 Months: -26.00%
6 Months: -38.27%
1 Year: -52.37%
YTD: -24.04%
Company Details
Employees: 176
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.